Molecular monitoring of hematologic malignancies: Current and future issues
- 1 April 2002
- journal article
- review article
- Published by Elsevier in Seminars in Hematology
- Vol. 39 (2) , 14-17
- https://doi.org/10.1053/shem.2002.33609
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcriptsLeukemia, 2002
- Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual diseaseLeukemia, 1999
- Therapy of Molecular Relapse in Acute Promyelocytic LeukemiaBlood, 1999
- Molecular Remissions Induced by Liposomal-Encapsulated All-Trans Retinoic Acid in Newly Diagnosed Acute Promyelocytic LeukemiaBlood, 1999
- Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARα Fusion Gene in Patients With Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter “AIDA” TrialBlood, 1998
- Diagnosis of acute promyelocytic leukaemia by RT‐PCR: detection of PML‐RARA and RARA‐PML fusion transcriptsBritish Journal of Haematology, 1992
- Molecular monitoring of the myl/retinoic acid receptor-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reactionBlood, 1992
- Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia.Proceedings of the National Academy of Sciences, 1992